4-Methoxybenzoic acid
CAS No. 100-09-4
4-Methoxybenzoic acid ( p-Anisic acid; NSC 32742 )
Catalog No. M17742 CAS No. 100-09-4
4-Methoxybenzoic acid could be used as raw material in cosmetic and dermatologic products and/or aroma components in foodstuffs, it has antiinflammatory and antimicrobial activities.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | 41 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4-Methoxybenzoic acid
-
NoteResearch use only, not for human use.
-
Brief Description4-Methoxybenzoic acid could be used as raw material in cosmetic and dermatologic products and/or aroma components in foodstuffs, it has antiinflammatory and antimicrobial activities.
-
Descriptionp-Anisic acid, also known as 4-methoxybenzoic acid or draconic acid, is one of the isomers of anisic acid. The term "anisic acid" often refers to this form specifically. p-Anisic acid is found naturally in anise.
-
Synonymsp-Anisic acid; NSC 32742
-
PathwayAngiogenesis
-
TargetCDK
-
Recptorantibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number100-09-4
-
Formula Weight152.14
-
Molecular FormulaC8H8O3
-
Purity98%
-
Solubility——
-
SMILESCOC1=CC=C(C=C1)C(=O)O
-
Chemical NameBenzoic acid, 4-methoxy-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
-
ICEC 0942
ICEC 0942 (CT7001) is a potent, selective, orally active CDK7 inhibitor with IC50 of 41 nM, displays 15-fold selectivity over CDK2 (IC50=578 nM)
-
Furanodiene
Furanodiene has anti-inflammatory and antioxidant activities, it is active against gram-positive bacteria and Candida albicans.The in vitro effects of Furanodiene were examined on two human breast cancer cell lines, MCF-7 and MDA-MB-231 cells.